CD47 and neoplasm: Therapeutic efficacy proved dependent on both PEP20-mediated CD47 blockade and ferroptosis induction, as evidenced by diminished tumor control in PEP20-deficient (ix group) and deferoxamine-treated (xi group) cohorts (Fig. 16g).